BIOLl 351l BIOL351l Modulel 9:l Latestl

BIOLl 351/l BIOL351l Modulel 9:l (Latestl

2026/l 2027l Update)l 100%l Verifiedl Questionsl &l Answersl |l Gradel A

Q:l Describel thel pathophysiologyl ofl rheumatoidl arthritisl (RA):

A)l RAl involvesl chronicl autoimmunel inflammationl andl tissuel damagel inl thel joints.B)l RAl isl al virall infectionl thatl affectsl thel liver.C)l RAl primarilyl causesl symptomsl inl thel digestivel tract.D)l RAl isl anl acutel bacteriall infection.

Answer:

A)l RAl involvesl chronicl autoimmunel inflammationl andl tissuel damagel inl thel joints.

Q:l Whatl isl al commonl symptoml ofl Hepatitisl Cl inl itsl chronicl stage?

A)l Numbnessl inl limbs B)l Severel abdominall pain C)l Fatiguel andl poorl appetite D)l Frequentl headaches

Answer:

C)l Fatiguel andl poorl appetite

Q:l Whichl ofl thel followingl isl al characteristicl ofl specialtyl medications?

A)l Lowl cost B)l Easilyl accessiblel atl alll pharmacies C)l Complexl treatmentl regimensl requiringl ongoingl monitoring D)l Lackl ofl speciall handlingl orl storagel requirements

Answer: 1 / 4

Answer:l C)l Complexl treatmentl regimensl requiringl ongoingl monitoring

Q:l Whol mayl definel whatl isl consideredl al specialtyl medicationl forl reimbursementl purposes?

A)l Thel patient B)l Thel manufacturer C)l Payersl (insurancel companies) D)l Thel pharmacist

Answer:

Answer:l C)l Payersl (insurancel companies)

Q:l Specialtyl medicationsl arel ________l derivedl andl availablel inl injection,l infusion,l orl orall form.

Answer:

biologically

Q:l Truel orl False:l Specialtyl medicationsl arel typicallyl lowl cost.

Answer:

False

Q:l Truel orl False:l Adalimumabl (Humira)l isl administeredl asl anl intravenousl (IV)l infusionl everyl otherl week.

Answer:

Falsel (It'sl al subcutaneousl injectionl everyl otherl week)

Q:l Whatl doesl Bevacizumabl (Avastin)l targetl tol treatl metastaticl colorectall cancer? 2 / 4

Answer:

Vascularl endotheliall growthl factor

Q:l Whichl classl ofl drugl doesl Infliximabl (Remicade)l belongl to?

A)l Anti-TNFl monoclonall antibody B)l Interleukinl receptorl antagonist C)l Selectivel costimulationl modulator D)l Humanl recombinantl IL-2l analogue

Answer:

Answer:l A)l Anti-TNFl monoclonall antibody

Q:l Whichl drugl isl indicatedl forl thel treatmentl ofl metastaticl renall celll carcinomal orl melanoma?

A)l Adalimumabl (Humira) B)l Aldesleukinl (Proleukin) C)l Etanerceptl (Enbrel) D)l Abataceptl (Orencia)

Answer:

Answer:l B)l Aldesleukinl (Proleukin)

Q:l Natalizumabl (Tysabri)l worksl byl targetingl whichl partl ofl thel immunel system?

A)l Tumorl necrosisl factorl (TNF) B)l Interleukin-1l receptor C)l Vascularl endotheliall growthl factor D)l Alpha4l integrinl subunit

Answer:

Answer:l D)l Alpha4l integrinl subunit 3 / 4

Q:l ________l (Kineret)l isl al dailyl subcutaneousl injectionl usedl tol treatl rheumatoidl arthritisl byl inhibitingl thel bindingl ofl IL-1l tol itsl receptorl sites.

Answer:

Anakinra

Q:l ________l (Avastin)l isl administeredl asl anl IVl infusionl everyl 14l daysl tol treatl metastaticl colorectall cancerl byl inhibitingl vascularl endotheliall growthl factor.

Answer:

Bevacizumab

Q:l Selectl thel falsel statementl aboutl Abataceptl (Orencia):

A)l Itl isl al selectivel costimulationl modulator.B)l Itl isl indicatedl forl thel treatmentl ofl rheumatoidl arthritis.C)l Itl isl administeredl asl al dailyl subcutaneousl injection.D)l Itl worksl byl inhibitingl T-celll activation.

Answer:

Answer:l C)l Itl isl administeredl asl al dailyl subcutaneousl injection.l (It'sl anl IVl infusionl everyl fourl weeks)

Q:l Matchl thel drugl withl itsl correspondingl drugl class: a.l Adalimumabl (Humira);l b.l Bevacizumabl (Avastin);l c.l Anakinral (Kineret);l d.l Etanerceptl (Enbrel)

i)l Anti-TNFl monoclonall antibod ii)l Antihumanl vascularl endotheliall growthl factor iii)l IL-1l receptorl antagonist iv)l TNFl receptorl antagonist

• / 4